- Home
- NCRA vs BCDA Comparison
NCRA vs BCDA Comparison
Compare NCRA & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCRA
- BCDA
- Stock Information
- Founded
- NCRA 2002
- BCDA N/A
- Country
- NCRA Taiwan
- BCDA United States
- Employees
- NCRA N/A
- BCDA N/A
- Industry
- NCRA Farming/Seeds/Milling
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- NCRA Consumer Staples
- BCDA Health Care
- Exchange
- NCRA Nasdaq
- BCDA Nasdaq
- Market Cap
- NCRA 16.1M
- BCDA 13.7M
- IPO Year
- NCRA N/A
- BCDA N/A
- Fundamental
- Price
- NCRA $1.01
- BCDA $1.37
- Analyst Decision
- NCRA
- BCDA Strong Buy
- Analyst Count
- NCRA 0
- BCDA 1
- Target Price
- NCRA N/A
- BCDA $25.00
- AVG Volume (30 Days)
- NCRA 1.9M
- BCDA 92.8K
- Earning Date
- NCRA 11-14-2025
- BCDA 11-12-2025
- Dividend Yield
- NCRA N/A
- BCDA N/A
- EPS Growth
- NCRA N/A
- BCDA N/A
- EPS
- NCRA N/A
- BCDA N/A
- Revenue
- NCRA $14,106,275.00
- BCDA N/A
- Revenue This Year
- NCRA N/A
- BCDA N/A
- Revenue Next Year
- NCRA N/A
- BCDA N/A
- P/E Ratio
- NCRA N/A
- BCDA N/A
- Revenue Growth
- NCRA N/A
- BCDA N/A
- 52 Week Low
- NCRA $0.70
- BCDA $1.00
- 52 Week High
- NCRA $2.40
- BCDA $3.20
- Technical
- Relative Strength Index (RSI)
- NCRA 34.29
- BCDA 53.97
- Support Level
- NCRA $0.94
- BCDA $1.27
- Resistance Level
- NCRA $1.14
- BCDA $1.34
- Average True Range (ATR)
- NCRA 0.12
- BCDA 0.07
- MACD
- NCRA -0.02
- BCDA 0.02
- Stochastic Oscillator
- NCRA 17.74
- BCDA 100.00
About NCRA Nocera Inc.
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).